Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 558Leukemia 281Precursor Cell Lymphoblastic Leukemia-Lymphoma 231Lymphoma 159Myelodysplastic Syndromes 110Burkitt Lymphoma 90Congenital Abnormalities 85Lymphoma, Non-Hodgkin 84Leukemia, Monocytic, Acute 83Leukemia, Myelomonocytic, Acute 81Lymphoma, Large B-Cell, Diffuse 79Leukemia, Erythroblastic, Acute 74Leukemia, Megakaryoblastic, Acute 71Recurrence 69Lymphoma, Mantle-Cell 69Lymphoma, Follicular 48Leukemia, Myelomonocytic, Chronic 43Leukemia, Biphenotypic, Acute 43Hodgkin Disease 43Lymphoma, Large-Cell, Immunoblastic 36Blast Crisis 36Anemia, Refractory, with Excess of Blasts 36Leukemia, Myelogenous, Chronic, BCR-ABL Positive 35Leukemia, Lymphocytic, Chronic, B-Cell 32Myeloproliferative Disorders 30Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 27Lymphoma, B-Cell, Marginal Zone 23Leukemia, Myeloid, Chronic-Phase 23Leukemia, Eosinophilic, Acute 23Leukemia, Basophilic, Acute 22

Interventions

venetoclax 1olutasidenib 1magrolimab 1fludarabine 1cc-486 1Mitoxantrone 1Etoposide 1Dexamethasone 1Decitabine 1Cytarabine 1Cyclophosphamide 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Myeloid Malignancies × Cytarabine × Clear all
NCT04778410 2025-03-20

Study of Magrolimab Combinations in Participants With Myeloid Malignancies

Gilead Sciences

Phase 2 Terminated
54 enrolled 26 charts

Myeloid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡